the use of sn-protoporphyrin or related synthetic heme analogues to diminish the severity of hyperbilirubinemia in newborn infants merits further study because inhibition of the rate-limiting enzyme in the catabolism of heme to bilirubin may prove to be a useful therapeutic approach in the clinical management of neonatal hyperbilirubinemia , especially in settings in which , for social or economic reasons , other treatment modalities are not available .
C0020433
hyperbilirubinemia
C0857007
neonatal